Rodrigo Liberal1, Charlotte R Grant2, Yun Ma2, Eva Csizmadia3, Zhenghui Gordon Jiang3, Michael A Heneghan2, Eric U Yee4, Giorgina Mieli-Vergani5, Diego Vergani2, Simon C Robson3, Maria Serena Longhi6. 1. Department of Liver Studies, Division of Transplantation Immunology & Mucosal Biology, MRC Centre for Transplantation, King's College London, Faculty of Life Sciences & Medicine, London, UK; Gastroenterology Department, Centro Hospitalar São João, Faculty of Medicine of the University of Porto, Porto, Portugal. 2. Department of Liver Studies, Division of Transplantation Immunology & Mucosal Biology, MRC Centre for Transplantation, King's College London, Faculty of Life Sciences & Medicine, London, UK. 3. Division of Gastroenterology, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard University, Boston, USA. 4. Department of Pathology, Beth Israel Deaconess Medical Center, Boston, USA. 5. Department of Liver Studies, Division of Transplantation Immunology & Mucosal Biology, MRC Centre for Transplantation, King's College London, Faculty of Life Sciences & Medicine, London, UK; Paediatric Liver, GI & Nutrition Centre, King's College London, Faculty of Life Sciences & Medicine, London, UK. 6. Department of Liver Studies, Division of Transplantation Immunology & Mucosal Biology, MRC Centre for Transplantation, King's College London, Faculty of Life Sciences & Medicine, London, UK; Division of Gastroenterology, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard University, Boston, USA. Electronic address: maria.longhi@kcl.ac.uk.
Abstract
BACKGROUND & AIMS: T-helper-type 17 (Th17) cells are involved in autoimmune tissue damage. CD39 is an ectonucleotidase that catalyzes extracellular ATP/ADP hydrolysis, culminating in the generation of immunosuppressive adenosine. Functional CD39 expression confers immunosuppressive properties upon immune cells. As the proportion of CD39 lymphocytes is decreased in juvenile autoimmune liver disease (AILD), we have explored whether decreased CD39 expression is present on Th17 cells and whether this phenomenon is associated with heightened effector function and inflammation. METHODS: Thirty-eight patients with juvenile AILD (22 autoimmune hepatitis and 16 autoimmune sclerosing cholangitis), 8 disease controls (DC) and 16 healthy subjects (HS) were studied. Peripheral blood cell phenotype was determined by flow cytometry; ability to suppress by inhibition of cell proliferation/effector cytokine production; ectoenzymatic activity by thin layer chromatography; expression of adenosine receptor, adenosine deaminase (ADA) and phosphodiesterases (PDE) by quantitative real-time PCR or by Western Blot. RESULTS: CD39(+) Th17 (Th17(CD39+)) cells from HS appear activated and contain high frequencies of lymphocytes producing regulatory cytokines. In AILD, however, Th17(CD39+) cells are markedly diminished and fail to generate AMP/adenosine, thereby limiting control of both target cell proliferation and IL-17 production. When compared to HS, Th17 cells from AILD patients also show lower A2A adenosine receptor expression while displaying similar levels of PDE4A, PDE4B and ADA. Only rare Th17(CD39+) cells are observed by liver immunohistochemistry. CONCLUSIONS: Th17(CD39+) cells in juvenile AILD are both quantitatively decreased and qualitatively deficient. Low levels CD39 and A2A expression may contribute to the perpetuation of Th17 cell effector properties and unfettered inflammation in this disease.
BACKGROUND & AIMS: T-helper-type 17 (Th17) cells are involved in autoimmune tissue damage. CD39 is an ectonucleotidase that catalyzes extracellular ATP/ADP hydrolysis, culminating in the generation of immunosuppressive adenosine. Functional CD39 expression confers immunosuppressive properties upon immune cells. As the proportion of CD39 lymphocytes is decreased in juvenile autoimmune liver disease (AILD), we have explored whether decreased CD39 expression is present on Th17 cells and whether this phenomenon is associated with heightened effector function and inflammation. METHODS: Thirty-eight patients with juvenile AILD (22 autoimmune hepatitis and 16 autoimmune sclerosing cholangitis), 8 disease controls (DC) and 16 healthy subjects (HS) were studied. Peripheral blood cell phenotype was determined by flow cytometry; ability to suppress by inhibition of cell proliferation/effector cytokine production; ectoenzymatic activity by thin layer chromatography; expression of adenosine receptor, adenosine deaminase (ADA) and phosphodiesterases (PDE) by quantitative real-time PCR or by Western Blot. RESULTS: CD39(+) Th17 (Th17(CD39+)) cells from HS appear activated and contain high frequencies of lymphocytes producing regulatory cytokines. In AILD, however, Th17(CD39+) cells are markedly diminished and fail to generate AMP/adenosine, thereby limiting control of both target cell proliferation and IL-17 production. When compared to HS, Th17 cells from AILD patients also show lower A2A adenosine receptor expression while displaying similar levels of PDE4A, PDE4B and ADA. Only rare Th17(CD39+) cells are observed by liver immunohistochemistry. CONCLUSIONS: Th17(CD39+) cells in juvenile AILD are both quantitatively decreased and qualitatively deficient. Low levels CD39 and A2A expression may contribute to the perpetuation of Th17 cell effector properties and unfettered inflammation in this disease.
Authors: Richard H Duerr; Kent D Taylor; Steven R Brant; John D Rioux; Mark S Silverberg; Mark J Daly; A Hillary Steinhart; Clara Abraham; Miguel Regueiro; Anne Griffiths; Themistocles Dassopoulos; Alain Bitton; Huiying Yang; Stephan Targan; Lisa Wu Datta; Emily O Kistner; L Philip Schumm; Annette T Lee; Peter K Gregersen; M Michael Barmada; Jerome I Rotter; Dan L Nicolae; Judy H Cho Journal: Science Date: 2006-10-26 Impact factor: 47.728
Authors: Yu Chen; Ross Corriden; Yoshiaki Inoue; Linda Yip; Naoyuki Hashiguchi; Annelies Zinkernagel; Victor Nizet; Paul A Insel; Wolfgang G Junger Journal: Science Date: 2006-12-15 Impact factor: 47.728
Authors: G V Gregorio; B Portmann; J Karani; P Harrison; P T Donaldson; D Vergani; G Mieli-Vergani Journal: Hepatology Date: 2001-03 Impact factor: 17.425
Authors: Bruce W Kirkham; Marissa N Lassere; John P Edmonds; Katherine M Juhasz; Paul A Bird; C Soon Lee; Ron Shnier; Ian J Portek Journal: Arthritis Rheum Date: 2006-04
Authors: Gerald G Krueger; Richard G Langley; Craig Leonardi; Newman Yeilding; Cynthia Guzzo; Yuhua Wang; Lisa T Dooley; Mark Lebwohl Journal: N Engl J Med Date: 2007-02-08 Impact factor: 91.245
Authors: Silvia Deaglio; Karen M Dwyer; Wenda Gao; David Friedman; Anny Usheva; Anna Erat; Jiang-Fan Chen; Keiichii Enjyoji; Joel Linden; Mohamed Oukka; Vijay K Kuchroo; Terry B Strom; Simon C Robson Journal: J Exp Med Date: 2007-05-14 Impact factor: 14.307
Authors: Anyan Xie; René J Robles; Samiran Mukherjee; Haohai Zhang; Linda Feldbrügge; Eva Csizmadia; Yan Wu; Keiichi Enjyoji; Alan C Moss; Leo E Otterbein; Francisco J Quintana; Simon C Robson; Maria Serena Longhi Journal: J Autoimmun Date: 2018-08-08 Impact factor: 7.094
Authors: C R Grant; B S Holder; R Liberal; M A Heneghan; Y Ma; G Mieli-Vergani; D Vergani; M S Longhi Journal: Clin Exp Immunol Date: 2017-03-27 Impact factor: 4.330
Authors: Rodrigo Liberal; Charlotte R Grant; Muhammed Yuksel; Jonathon Graham; Alireza Kalbasi; Yun Ma; Michael A Heneghan; Giorgina Mieli-Vergani; Diego Vergani; Maria Serena Longhi Journal: Hepatology Date: 2017-10-03 Impact factor: 17.425
Authors: Marta Vuerich; Rasika Harshe; Luiza Abrahão Frank; Samiran Mukherjee; Barbora Gromova; Eva Csizmadia; Imad A M Nasser; Yun Ma; Alan Bonder; Vilas Patwardhan; Simon C Robson; Maria Serena Longhi Journal: J Hepatol Date: 2020-07-11 Impact factor: 25.083